hrp0089s7.1 | Bone | ESPE2018

X-linked Hypophosphataemic Rickets: Disease and Treatment

Linglart Agnes

XLH is a dominant disorder with a prevalence of approximately 1.7/100,000 children to 4.8/100,000 persons. PHEX, the gene responsible for XLH was identified on chromosome Xp22. It codes for a cell surface-bound protein-cleaving enzyme expressed predominantly in bone and teeth. The altered function of PHEX causes both the mineralization defect and the renal phenotypic abnormalities of XLH. Clinical manifestations of XLH occur most often around the age of walki...

hrp0082s1.3 | Disorders of Gsalpha Signaling | ESPE2014

New Therapies in Metabolic Bone Disease: PTH

Linglart Agnes

Hypoparathyroidism is a rare disease manifesting as hypocalcemic seizures, developmental delay, sluggishness, paresthesias and/or dyskinesia. Symptoms reveal hypocalcaemia associate with increased serum phosphorus and undetectable, low or unadapted PTH levels. Known causes of hypoparathyroidism are cervical surgeries causing irreversible damage to the parathyroid tissue, toxic attack of the parathyroid cells by antibodies, and genetic defects affecting parathyroid development,...

hrp0086p2-p641 | Growth P2 | ESPE2016

Hypochondroplasia (HC) Treatment with rGH: Actualization of Pilot Observations

Bougneres Pierre , Linglart Agnes

Background: In patients with HC due to N540K FGFR3 mutations, adult height ranges 138–155 cm (men) and 128–145 cm in women. We have previously reported that a mean 0.075 μg/k.d rGH dose could allow a gain of 1.9 S.D. of height over 6.1 year and could reduce body disproportion in 6 young patients (Journal of Pediatrics 2012).Objectives: To confirm these results and extend observation of rGH effects.<p class="abst...

hrp0098s2.3 | Bone and Mineral Disorders: Recent Developments | ESPE2024

PTH Resistance Syndromes

Linglart Agnès

Pseudohypoparathyroidism, or syndromes associated with PTH resistance, share a common defect in the PTH1R/Gsalpha/cAMP signaling pathway. Therefore, this entity is now labeled as “inactivating PTH/PTHrP disorder” or iPPSD. IPPSD is a genetic disorder characterized by target-organ unresponsiveness to PTH and/or PThrP. it mimics hypoparathyroidism, as patients present with hypocalcemia and hyperphosphatemia; however, due to an abnormal signaling pathway downstream of...

hrp0094p2-27 | Adrenals and HPA Axis | ESPE2021

High doses op’-DDD cause metrorragia in young girls

Thomas-Teinturier Cecile , Bouvattier Claire , Linglart Agnes ,

Gynecomastia is a well-known effect of treatment with op’-DDD in male adults. Metrorragia in young girls is a less known effect because only a few children receive this drug, mostly for bad prognosis adrenocortical carcinoma. Moreover, it has been reported that op’DDD causes precocious puberty, but cases are not well documented. We report 2 cases of young girls receiving high-dose op’-DDD who presented recurrent metrorragia. Case 1: An 18 month old girl was diag...

hrp0095p1-551 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Impact of the COVID 19 pandemic on the incidence of precocious puberty

Trouvin Marie-Agathe , Thomas-Teinturier Cécile , Linglart Agnès

The 1st lockdown from March to May 2020 probably led to an increase in the number of cases of idiopathic central precocious puberty in several European countries. Two Italian studies showed this, as well as a Spanish and a Turkish one. We performed a retrospective study with all the children who came to our department for a 1st appointment or a check-up for pubertal signs between 01/04/2017 and 31/03/2021. We checked the data of 765 files and kept only the children with a diag...

hrp0089p2-p041 | Bone, Growth Plate &amp; Mineral Metabolism P2 | ESPE2018

Clinical and Biological Parameters Associated to the Severity of X-linked Hypophosphatemia in Children

Salcion-Picaud A , Rothenbuhler A , Etcheto A , Molto A , Briot K , Linglart A

Introduction: X-linked hypophosphatemia or XLH is a rare genetic disease, often revealed in children by rickets, growth failure, delayed walking, and leg bowing. Clinically the severity is reflected by leg deformities. The aim of our study was to assess the clinical and biochemical parameters correlated to the severity of XLH at the end of growth.Materiel and methods: Monocentric retrospective study of patients treated with phosphate supplements and vita...

hrp0086fc2.1 | Bone &amp; Mineral Metabolism | ESPE2016

Characterization of GNAS miRNAs Targets: Trying to Better Understand the Pathophysiology of Pseudohypoparathyroidism 1B (PHP1B)

Hanna Patrick , Netchine Irene , Le Stunff Catherine , Linglart Agnes

Background: Patients affected with PHP1B are characterized by resistance to PTH which binds to the PTH receptor and activate the cAMP/Gsa signaling pathway. Gsa is encoded by GNAS, a locus subjected to genomic imprinting. PHP1B patients present with abnormal methylation at the maternal A/B promoter and, in some cases, at the other promoters (XLas, GNAS-AS1 and NESP55) of the GNAS locus, likely leading to a decreased express...

hrp0086p1-p101 | Bone &amp; Mineral Metabolism P1 | ESPE2016

Effect of Bisphosphonates on Bone Fragility Due to Chronic Liver Disease in Ten Children

Gonzales Emmanuel , Darce Martha , Usardi Alessia , Linglart Agnes

Background: Children suffering from chronic liver disease (CLD) may develop rickets, impaired bone mineralization and are exposed to an increased risk of osteoporotic fractures. Bisphosphonate (BP) is used in children to increase the bone density and reduce the fracture incidence. Up to date, no study showing the effect of this treatment in children suffering from CLD has been reported.Objective and hypotheses: Evaluate the effect of BPs in children with...

hrp0086p2-p151 | Bone &amp; Mineral Metabolism P2 | ESPE2016

Progressive Development of PTH Resistance in Patients with Maternal GNAS Inactivating Mutations

Usardi Alessia , Mamoune Asmaa , Nattes Elodie , Rothenbuhler Anya , Linglart Agnes

Background: Pseudohypoparathyroidism (PHP) is a group of disorders characterized by end-organ resistance to the parathyroid hormone (PTH). PHP type 1A is caused by mutations in GNAS exon 1 through 13 with multihormone resistance (PTH, TSH and gonadotropins), Albright’s hereditary osteodystrophy, and obesity. However, patients often do not present with elevated levels of PTH until after the first years of life.O...